Compare AEYE & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | LONA |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.9M | 83.7M |
| IPO Year | 2011 | N/A |
| Metric | AEYE | LONA |
|---|---|---|
| Price | $6.25 | $10.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.63 | $10.00 |
| AVG Volume (30 Days) | ★ 240.5K | 76.5K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,311,000.00 | N/A |
| Revenue This Year | $11.33 | N/A |
| Revenue Next Year | $11.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $5.31 | $4.21 |
| 52 Week High | $16.39 | $14.21 |
| Indicator | AEYE | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 66.87 |
| Support Level | $5.40 | $4.52 |
| Resistance Level | $9.27 | $14.21 |
| Average True Range (ATR) | 0.47 | 1.77 |
| MACD | 0.18 | 0.09 |
| Stochastic Oscillator | 47.79 | 45.52 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).